| scholarly article | Q13442814 |
| P50 | author | Paul D. Cotter | Q37830651 |
| Colin Hill | Q37830656 | ||
| Aidan Coffey | Q43247937 | ||
| Jim O'Mahony | Q102065421 | ||
| P2093 | author name string | R Paul Ross | |
| Paula M O'Connor | |||
| James Carroll | |||
| Lorraine A Draper | |||
| P433 | issue | 2 | |
| P304 | page(s) | 132-136 | |
| P577 | publication date | 2010-05-23 | |
| P1433 | published in | International Journal of Antimicrobial Agents | Q15724616 |
| P1476 | title | Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria | |
| P478 | volume | 36 |
| Q57490149 | A Review: The Fate of Bacteriocins in the Human Gastro-Intestinal Tract: Do They Cross the Gut-Blood Barrier? |
| Q38851130 | A conserved streptococcal membrane protein, LsrS, exhibits a receptor-like function for lantibiotics |
| Q38056436 | Anti-infective properties of bacteriocins: an update |
| Q87107449 | Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria |
| Q37712986 | Energy metabolism and drug efflux in Mycobacterium tuberculosis |
| Q41695546 | Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents |
| Q42085729 | Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs |
| Q64899486 | Lactic acid Bacteria isolated from European badgers (Meles meles) reduce the viability and survival of Bacillus Calmette-Guerin (BCG) vaccine and influence the immune response to BCG in a human macrophage model. |
| Q41858889 | Lantibiotics as prospective antimycobacterial agents |
| Q92704112 | Looking beyond Typical Treatments for Atypical Mycobacteria |
| Q28082317 | Natural antimicrobial peptides against Mycobacterium tuberculosis |
| Q40854351 | Overexpression, purification, crystallization and preliminary X-ray diffraction of the nisin resistance protein from Streptococcus agalactiae |
| Q37569003 | Saturation mutagenesis of selected residues of the α-peptide of the lantibiotic lacticin 3147 yields a derivative with enhanced antimicrobial activity |
| Q63342979 | Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis |
| Q58455863 | The Case of Lipid II: The Achilles’ Heel of Bacteria |
| Q55004027 | The Impact of the Antimicrobial Compounds Produced by Lactic Acid Bacteria on the Growth Performance of Mycobacterium avium subsp. paratuberculosis. |
| Q35691679 | The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model. |
| Q58797800 | The potency of the broad spectrum bacteriocin, bactofencin A, against staphylococci is highly dependent on primary structure, N-terminal charge and disulphide formation |
| Q31140261 | The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. |
| Q37106265 | Thusin, a Novel Two-Component Lantibiotic with Potent Antimicrobial Activity against Several Gram-Positive Pathogens |
Search more.